

Valeant Pharmaceuticals International, Inc.
Form 8-K
June 24, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): June 24, 2013

Valeant Pharmaceuticals International, Inc.

(Exact name of registrant as specified in its charter)

Canada
(State or other jurisdiction

of incorporation)

001-14956
(Commission

File Number)

98-0448205
(IRS Employer

Identification No.

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 8-K

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada H7L 4A8

(Address of principal executive offices)(Zip Code)

514-744-6792

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CAR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CAR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CAR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

Item 8.01 Other Events.

On June 24, 2013, Valeant Pharmaceuticals International, Inc. (the Company) completed, pursuant to an Underwriting Agreement with Goldman, Sachs & Co. and Goldman Sachs Canada Inc., the sale of 27,058,824 shares of its common stock, no par value (the Shares). The Shares were registered under the Securities Act of 1933 pursuant to a registration statement on Form S-3 (File No. 333-189192) that was filed with the Securities and Exchange Commission on June 10, 2013.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number	Description
1.1	Underwriting Agreement, dated June 18, 2013, among the Company, Goldman, Sachs & Co. and Goldman Sachs Canada Inc.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

By: /s/ Howard B. Schiller
Name: Howard B. Schiller
Title: Executive Vice President and Chief Financial
Officer

Date: June 24, 2013

EXHIBIT INDEX

Exhibit

Number	Description
1.1	Underwriting Agreement, dated June 18, 2013, among the Company, Goldman, Sachs & Co. and Goldman Sachs Canada Inc.